Development of maintenance treatment about rheumatoid arthritis in remission

Abstract

Abstract: Rheumatoid arthritis (RA) is a kind of complex and multi-system autoimmune disease with the main characteristics of the inflammation in joints .About the drug use of RA in remission is always a difficult and hot problem in rheumatology academia for a long time. In recent years, with the maturity of DMARDs and the rapid development of biological agents, the maintenance treatment and drug selection in RA is more flexible. New breakthrougs about curative effect, prognosis and the control of adverse events have been made in the past few years. Now the maintenance treatment of rheumatoid arthritis in remission was reviewed.

Key words: Rheumatoid arthritis, Remission, Treatment

CLC Number:

R392

LI Xiao-xin, XU Liang. Development of maintenance treatment about rheumatoid arthritis in remission[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 116-120.

References

[1] Ruderman EM,Nola KM, Ferrell S,et al. Incorporating the treat-to-target concept in rheumatoid arthritis[J].Manag Care Pharm,2012 ,18(9):1-18.
[2] Pinals RS, Baum J,Bland J,et al.Preliminary criteria for clinical remission in rheumatoid arthritis[J].Bull Rheum Dis,1982,32(1):7-10.
[3] Felson DT, Smolen JS,Wells G,et al.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials[J].Arthritis Rheum,2011 ,63(3):573-586.
[4] Ranganath VK,KhannaD,PaulusHE,et al. ACR remission criteria and response criteria[J].Clin Exp Rheumato,2006,24(43):S14-S21.
[5] Silva LK, Ortiz AM, Patiño E,et al.Influence of the structure of mood in the assessment of rheumatoid arthritis through the visual analog scale for pain,HAQ and DAS28[J].Reumatol Clin,2012,8(6):328-333.
[6] Mãkinen H,Hannonen P, Sokka T.Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinicaltrials for the rate of remission[J].Clin Exp Rheumatol,2006,24(6):22-28.
[7] Smolen JS,Breedveld FC, Schiff MH,et al.A simplified disease activity index for rheumatoid arthritis for use in clinical practice[J].Rheumatology (Oxford),2003,42(2):244-257.
[8] Rotar Z,Praprotnik S,Tomšic M.Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials:Comment on the article by Felson et al[J].Arthritis Rheum,2011 ,63(11):3642-3643.
[9] Smolen JS,Aletaha D,Bijilsma JWJ,et al.Treating rheumatoid arthritis to target: recommendations of an international task force[J].Ann Rheum Dis,2010,69 :631-637.
[10] Foltz V, Gandjbakhch F,Fautrel B,et al.Management of patients with rheumatoid arthritis in remission[J].Rev Prat,2012 ,62(8):1107-1112.
[11] Wessels JA,Vries-Bouwstra JK, Heijmans BT,et al.Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzyme[J].Arthritis Rheum,2006 ,54(4):1087-1095.
[12] Aletaha　D,Stamm　T,Kapral T,et al.Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study[J].Ann Rheum Dis,2003,62(10):944-951.
[13] Dervieux T,Zablocki R,Kremer J, et al.Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis[J].Rheumatology (Oxford),2010 ,49(12):2337-2345.
[14] Baggott JE, Morgan SL.Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate[J].Am J Clin Nutr,2008 ,88(2):479-480.
[15] Prabhu P,Shetty R, Koland M, et al.Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity[J].Int J Nanomedicine,2012,7:177-186.
[16] Emery P,Breedveld FC,Lemmel EM,et al.A comparison of the ef-i cacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis[J].Rheumatology,2000,39(6): 655-665.
[17] Wiacek R,Kolossa K,Jankowski T,et al.The efficacy and safety of leflunomide in patients with active rheumatoid arthritis[J].Adv Clin Exp Med,2012 ,21(3):337-342.
[18] McLaren ZL,Dawson JK.Comment on: Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid　arthritis[J].Rheumatology (Oxford), 2010,49(8):1606.
[19] Gabelle　A,Antoine JC,Hillaire　BD,et al.Leflunomide related severe　axonalneuropathy [J]. RevNeuro, 2005,161(11): 1106-1109.
[20] Lie E,Uhlig T,Heijde D,et al.Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA[J]. Rheumatology (Oxford),2012,51(4).670-678.
[21] Guin A, Chatterjee AM,Chakraborty S,et al.Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in　early rheumatoid arthritis:1-year follow-up study[J].Semin Arthritis Rheum,2013,12(13):48-54.
[22] Hara M,Abe T,Sugawara S,et al.Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study[J].Mod Rheumatol,2007,17(1):1-9.
[23] Furukawa K,Ohtani T, Furukawa F,et al.Infectious mononucleosis-like syndrome induced by salazosulfapyridine in a patient with rheumatoid arthritis[J].Mod Rheumatol,2007,17(6):492-495.
[24] Nakayama S,Yokote T,Kobayashi K,et al.Megaloblastic anemia associated with salazosulfapyridine treatment for rheumatoid arthritis[J].Rinsho Ketsueki, 2008,49(12):1609-1613.
[25] Kim WU,Yoo SA,Min SY,et al.Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes[J].Clin Exp Immunol, 2006,144(3):503-511.
[26] Saadat F,Cuzzocrea S,Di Paola R,et al.Effect of pyrimethamine in experimental rheumatoid arthritis[J]. Med Sci Monit,2005,11(8) :29.
[27] Rao AN,Shetty BV, Vasudevan DM,et al.Positive influence of Methotrexate-Hydroxychloroquine combination onthe expression of GM-CSF receptor onneutrophils of synovial fluid in rheumatoid arthritis[J].Indian J Clin Biochem,2006,21(2):49-52.
[28] Kavanaugh A,Fleischmann RM,Emery P,et al.Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study[J].Ann Rheum Dis,2013,72(1):64-71.
[29] Mukai Y,Nakamura T,Yoshikawa M,et al.Solution of the structure of the TNF-TNFR2 complex[J].Sci Signal,2010,3(148):ra83.
[30] Horton S,Maya H Buch,Paul emery,et al.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations[J].Drug Healthc Patient Saf,2010,2:101-119.
[31] Shale M,Scow C,Cofin C,et al.Review article:chronic viral infeetion in the antitumor necrosis factor therapy era in inflammatory bowel disease[J].Aliment Pharmacol Therap,2010,31(1):20-34.
[32] Bongartz T,Sutton AJ,Sweeting MJ,et al.Anti-TNF antibody therapy in rheumatoid arthritis andthe riskof serious infections and malignancies: systematicreview and meta-analysis of rare harmful effects in randomized controlled trials[J].JAMA,2006,295:2275-2285.
[33] Setoguchi S, Solomon DH,Weinblatt ME,et al.Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis[J].Arthritis Rheum, 2006,54(9):2757-2764.